-
Nat Commun: Immune cell steroids or the activity of the host immune system that helps tumors suppress hosts are expected to help develop new cancer immunotherapy treatments.
Time of Update: 2020-08-27
August 7, 2020 // -- In a recent study published in the international journal Nature Communications, scientists from the Sanger Institute and other institutions in the United Kingdom found that tumors
-
Nat Commun: Breakthrough! Scientists have successfully described the fine structure of viral proteins that could be used to develop new drugs for COVID-19!
Time of Update: 2020-08-27
August 7, 2020 // -- In a study published in the international journal Nature Communications, scientists from the Czech Academy of Sciences and other institutions have described a new strain of SARS-C
-
NMCD: Eating a soy-rich diet may affect the body's blood pressure by regulating the gut microbiome.
Time of Update: 2020-08-27
picture source: CC0 Public Domain, an international magazine, In a study published in Metabolism and Cardiovascular Diseases entitled "Soy food intake associates with changes in the metabolome and reduced blood pressure in a gut microbiota manner", scientists from Vanderburg University and other institutions found that ingestion of soybeans may affect the body's blood pressure by regulating the body's gut microbiome, a diverse bacteriological group that lives in the human body's gastrointestinal system.
-
Sci Adv: Chinese scientists have developed a new technique that promises to quickly lock down stomach cancer cells.
Time of Update: 2020-08-27
First, the researchers created a new OEK-based microflow chip to isolate gastric cancer cells from the patient's abdominal water and analyze their electrochemical characteristics, and then they created a cell polymerization model and a cell membrane capacitor solution model.
-
JEM: Research and development of SARS-coV-2 mouse models.
Time of Update: 2020-08-27
(Photo source: www.pixabay.com) In the new study, Professor Iwasaki's lab at Yale University School of Medicine developed another mouse model of SARS-CoV-2 infection, in which animals were first infected with another harmless virus carrying the human ACE2 gene.
-
Nat Genet: Scientists have discovered that a four-stranded DNA structure may play a key role in the development of breast cancer.
Time of Update: 2020-08-27
August 8, 2020 // -- In a recent study published in the international journal Nature Genetics, scientists from the University of Cambridge and other institutions found for the first time that a four-stranded DNA structure (G-quadruplexes) may play a key role in the development of specific types of breast cancer, and that the findings may provide potential new targets for the development of individualized breast cancer therapies.
-
Nat Microbiol: A special immunoprotein, LY6E, or infection that can damage SARS-Cov-2.
Time of Update: 2020-08-27
August 9, 2020 // -- A protein produced by the human immune system that may be effective in suppressing coronavirus infections, including SARS-Cov-2, may help develop new treatments for coronavirus in
-
Chronic sinusitis with nasal (CRSwNP) new drug! Novarro Xolair's new adaptations are approved by the European Union!
Time of Update: 2020-08-27
!--Webeditor:title"--August 07, 2020 // -- Novartis recently announced that the European Commission (EC) has approved the anti-inflammatory drug Xolair (Chinese brand name: Lying, generic name: omaliz omab, omajuma monotherapy) A new adaptive disorder, as an additional (add-on) therapy for endosinurtic steroids (INC), used to treat severe chronic nasal-sinusitis accompanied by nasal polyps (CRSwNP) adult patients with INC that do not adequately control the condition (AGE 18).
-
Immunity: The gut microbiome may be able to convert stress into sickle cell disease.
Time of Update: 2020-08-27
August 7, 2020 // -- In a study published in the international journal Immunity, scientists from the Albert Einstein College of Medicine and other institutions studied mice to show how chronic psychol
-
Xie Xiaoliang: The medium antibody is expected to become a special drug for new coronary pneumonia, which can be treated and prevented in the short term.
Time of Update: 2020-08-27
On August 8th, at the New Crown Therapeutic Antibody and Vaccine Forum of the HCare Global Health Industry Summit, Xie Xiaoliang, Director of the Center for Biomedical Frontier Innovation at Peking Un
-
Oncoimmunol: Immunotherapy can be used to treat malignant skin cancer.
Time of Update: 2020-08-26
9, 2020 /--- According to a recent study published in the journal OncoImmunology, researchers at the Karolinska Institute and the hospital have shown that new immunotherapy has significant effects on the treatment of malignant melanoma.
-
On August 7, 2020, Chinese scientists published three Science papers in the same period.
Time of Update: 2020-08-26
"3.Science: Using powerful medium and antibodies from COVID-19 patients to identify multiple vulnerable targets of the new coronary virus doi: 10.1126/science.abc5902 In a new study, from the Netherlands Researchers at the University of Amsterdam, Erasmus Medical Center, the Scripps Institute in the United States and Cornell University's Weir School of Medicine isolated 18 medium antibodies (NAbs) from three patients recovering from a stable fusion of pre-sting proteins from SARS-CoV-2.
-
New drug for mid-axis spina blinhroarthritis (axSpA)! Excellent time than Cimzia (Himinja) European label extension: continuous remission period can reduce the dose!
Time of Update: 2020-08-26
Cimzia's label expansion in Europe addresses under-recognized unsusced needs by providing the first documented dose reduction strategy for patients within the broad range of axSpA for continuous mitigation.
-
Cell: Revealing rising calcosin and abnormal bone marrow cell subse groups can distinguish between severe and mild patients with new coronary pneumonia.
Time of Update: 2020-08-26
study of so-called neutral granulocytes and monocytes, German researchers found that these immune cells have been activated, i.e. in mild cases, they are prepared to protect patients against COVID-19.
-
Immunity: The new method predicts body fluid immunity in COVID19 patients.
Time of Update: 2020-08-26
using systemic serological techniques to learn more about the body fluid immune response, Dr Alter's lab compared the immune responses of the recovering and deceased.
-
CLIN CHEM LAB MED: Changes in immunofluorescence test results for HEp-2 cell antinuclear antibodies reflect the disease activity status of systemic lupus erythematosus?
Time of Update: 2020-08-24
all subjects assessed the HEp-2 IFA titration and staining patterns, as well as the traditional parameters of nine SLE disease activities.
results show that the HEp-2 IFA pattern and titration reflect SLE disease activity and can be evaluated in conjunction with other laboratory and clinical parameters.
-
The FDA approved Lampit (nifurtimox) for the treatment of Chagas disease in children.
Time of Update: 2020-08-24
30 to 40 percent of people, more symptoms occur 10 to 30 years after the initial infection.
an estimated 7 to 8 million people are infected with Chagas disease, mostly in Mexico, Central and South America.
-
Nature: Immune "yin and yang" who regulates? HDAC3 protein is key.
Time of Update: 2020-08-24
if well organized, the inflammatory response can quickly and accurately locate and eliminate the risk, and then enter the anti-inflammatory process to help remove damaged tissue and allow the body to begin healing and repair.
-
Under-tongue film preparation AQST-108 therapeutic hypersensitive reaction: HAS been qualified for FDA fast-track.
Time of Update: 2020-08-24
specific IgE antibodies against a strain factor are the main factors that trigger the type I.
J. Kendall, chief executive of Aquestive, said: "Fast track eligibility confirms that the medical needs of hypersensitive responses have not yet been met.
-
Ann Intern Med: A full thyroidectomy improves the health-related quality of life and fatigue of Hashimoto disease, but medication does not.
Time of Update: 2020-08-24
, designed in a randomized trial, was conducted at a secondary health hospital in Norway and included 150 patients between the ages of 18 and 79 who, despite normal thyroid function, still had ongoing hassle-related symptoms while receiving hormone replacement therapy and serum anti-thyroid peroxide (anti-TPO) antibody titration greater than 1000 IU/mL.
